Enrique Zudaire Selected Research

Enrique Zudaire Research Topics

Disease

22	Neoplasms (Cancer) 11/2022 - 04/2002
9	Lung Neoplasms (Lung Cancer) 09/2019 - 09/2004
7	Multiple Myeloma 07/2023 - 01/2021
4	Carcinogenesis 11/2012 - 04/2002
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 09/2004
3	Neoplasm Metastasis (Metastasis) 10/2017 - 06/2014
2	Cytokine Release Syndrome 12/2023 - 01/2023
2	cell-associated neurotoxicity 12/2023 - 01/2023
2	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2023 - 01/2023
2	Pheochromocytoma 08/2006 - 04/2002
1	Disease Progression 07/2023
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2023
1	Residual Neoplasm 01/2023
1	Plasmablastic Lymphoma 01/2023
1	Starvation 11/2022
1	Prostatic Neoplasms (Prostate Cancer) 01/2022
1	Colorectal Neoplasms (Colorectal Cancer) 01/2022
1	Microsatellite Instability 01/2022
1	Melanoma (Melanoma, Malignant) 01/2022
1	Pneumonia (Pneumonitis) 02/2021
1	Fever (Fevers) 02/2021
1	Chills 02/2021
1	Colonic Neoplasms (Colon Cancer) 06/2014
1	Wolman Disease (Wolman's Disease) 11/2008
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 11/2008
1	Lung Injury 11/2008
1	Ovarian Neoplasms (Ovarian Cancer) 09/2008
1	Rhinosinusitis 05/2007
1	Breast Neoplasms (Breast Cancer) 05/2005
1	Adenocarcinoma 05/2005

Drug/Important Bio-Agent (IBA)

6	B-Cell Maturation AntigenIBA 07/2023 - 01/2021
5	Chimeric Antigen ReceptorsIBA 01/2023 - 01/2021
5	Proteins (Proteins, Gene)FDA Link 11/2022 - 09/2004
4	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 07/2023 - 01/2022
4	Messenger RNA (mRNA)IBA 09/2010 - 09/2004
3	Immunoconjugates (Immunoconjugate)IBA 01/2023 - 10/2017
3	AdrenomedullinIBA 08/2006 - 04/2002
2	AntigensIBA 01/2023 - 01/2022
2	Proteasome InhibitorsIBA 01/2023 - 01/2021
2	Membrane Proteins (Integral Membrane Proteins)IBA 11/2022 - 10/2017
2	LigandsIBA 01/2022 - 05/2005
2	AntibodiesIBA 01/2022 - 09/2004
2	Angiogenesis InhibitorsIBA 06/2014 - 09/2008
2	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 06/2014 - 09/2004
2	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 11/2012 - 02/2008
2	Small Interfering RNA (siRNA)IBA 02/2008 - 01/2006
2	Peptides (Polypeptides)IBA 09/2004 - 04/2002
2	Complement System Proteins (Complement)IBA 09/2004 - 04/2002
1	Lenalidomide (CC 5013)FDA Link 07/2023
1	Dihydrotachysterol (AT 10)IBA 01/2023
1	Bispecific AntibodiesIBA 01/2023
1	Glutamine (L-Glutamine)FDA Link 11/2022
1	CollagenIBA 11/2022
1	Neutralizing AntibodiesIBA 11/2022
1	triplex DNA (H-DNA)IBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Single-Domain AntibodiesIBA 01/2021
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 09/2019
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 09/2019
1	erdafitinibIBA 09/2019
1	ProdrugsIBA 01/2018
1	pyrrolo(2,1-c)(1,4)benzodiazepineIBA 10/2017
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2014
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 06/2014
1	Dinoprostone (PGE2)FDA Link 06/2014
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 04/2011
1	hnRNP A2IBA 09/2010
1	Cadherins (E-Cadherin)IBA 09/2010
1	Heterogeneous-Nuclear Ribonucleoprotein Group A-BIBA 09/2010
1	Bleomycin (Blenoxane)FDA LinkGeneric 11/2008
1	matrigelIBA 11/2008
1	inter-alpha-inhibitorIBA 11/2008
1	Hyaluronic Acid (Hyaluronan)IBA 11/2008
1	FilaminsIBA 09/2008
1	Indicators and Reagents (Reagents)IBA 09/2008
1	Transforming Growth Factor beta1 (TGF beta 1)IBA 06/2008
1	bombesin receptor subtype 3IBA 02/2008
1	Glucose (Dextrose)FDA LinkGeneric 02/2008
1	MucinsIBA 05/2007
1	compound 77427IBA 06/2005
1	Gastrin-Releasing PeptideIBA 06/2005
1	Angiogenic ProteinsIBA 06/2005
1	ciglitazoneIBA 05/2005
1	Cyclooxygenase InhibitorsIBA 05/2005
1	Arachidonic Acid (Vitamin F)IBA 05/2005
1	Isotretinoin (Accutane)FDA LinkGeneric 05/2005
1	Indomethacin (Indometacin)FDA LinkGeneric 05/2005
1	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)IBA 05/2005
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 05/2005
1	PPAR alphaIBA 05/2005
1	PPAR gammaIBA 05/2005
1	MK-886IBA 05/2005

Therapy/Procedure

17	Therapeutics 12/2023 - 06/2005
1	Blood Component Removal (Apheresis) 12/2023
1	Castration 01/2022
1	Immunotherapy 01/2022
1	Chemoprevention 08/2014
1	Transplantation 02/2008
1	Aftercare (After-Treatment) 05/2005